Inventiva S.A. (IVA) stock
IVANasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as IVEVF
$3.39+0.17 (+5.28%)
Close on Nov 18, 2026Market cap $655.07MP/E –Yield –
Inventiva operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -€141.01M. The highest annual figure on record is -€29.72M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€141.01M | – |
| FY2024 | Dec 31, 2024 | -€97.56M | – |
| FY2023 | Dec 31, 2023 | -€102.71M | – |
| FY2022 | Dec 31, 2022 | -€57.11M | – |
| FY2021 | Dec 31, 2021 | -€52.11M | – |
| FY2020 | Dec 31, 2020 | -€29.72M | – |
| FY2019 | Dec 31, 2019 | -€30.31M | – |
| FY2018 | Dec 31, 2018 | -€32.90M | – |
See a number that looks wrong?